Q1 2021 13F Holders as of 3/31/2021
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
293M
-
Number of holders
-
82
-
Total 13F shares, excl. options
-
70.6M
-
Shares change
-
+2.51M
-
Total reported value, excl. options
-
$2.4B
-
Value change
-
+$66M
-
Put/Call ratio
-
0.72
-
Number of buys
-
56
-
Number of sells
-
-31
-
Price
-
$33.96
Significant Holders of AbCellera Biologics Inc. - Ordinary Shares (ABCL) as of Q1 2021
105 filings reported holding ABCL - AbCellera Biologics Inc. - Ordinary Shares as of Q1 2021.
AbCellera Biologics Inc. - Ordinary Shares (ABCL) has 82 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 70.6M shares
of 293M outstanding shares and own 24.1% of the company stock.
Largest 10 shareholders include VIKING GLOBAL INVESTORS LP (19.1M shares), BAKER BROS. ADVISORS LP (10.5M shares), ORBIMED ADVISORS LLC (8.2M shares), SB Management Ltd (7.82M shares), Capital World Investors (4.16M shares), HARVARD MANAGEMENT CO INC (4.11M shares), Founders Fund VII Management, LLC (3.77M shares), Falcon Edge Capital, LP (2.43M shares), CREDIT SUISSE AG/ (2.27M shares), and Capital International Investors (1.8M shares).
This table shows the top 82 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.